GSC
NMRA icon

Ground Swell Capital’s Neumora Therapeutics NMRA Stock Holding History

Ground Swell Capital’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,790
Closed -$9.38K – 202
2025
Q2 		$9.38K Buy
+12,790
New +$9.69K 0.01% 125

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Ground Swell Capital's NMRA Position: Q3 2025 in Review

Ground Swell Capital sold out of Neumora Therapeutics (NMRA) in Q3 2025, closing a stake of 12,790 shares — an estimated $9.38K sold.

Ground Swell Capital first reported a position in NMRA in Q2 2025 and held it in 1 quarter. The position peaked at $9.38K in Q2 2025. 93 funds tracked by Wall St. Rank hold NMRA as of Q3 2025.

  • Ground Swell Capital reported no remaining Neumora Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Ground Swell Capital sold 12,790 Neumora Therapeutics shares in Q3 2025, an estimated $9.38K.
  • Ground Swell Capital first reported a position in Neumora Therapeutics in Q2 2025 and held it in 1 quarter.
  • Ground Swell Capital's Neumora Therapeutics position peaked at $9.38K in Q2 2025.
  • 93 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2025.

Based on Ground Swell Capital's 13F filing for Q3 2025, filed 6 Nov 2025.